AU2019328556B2 - Cardiac sarcomere inhibitors - Google Patents

Cardiac sarcomere inhibitors

Info

Publication number
AU2019328556B2
AU2019328556B2 AU2019328556A AU2019328556A AU2019328556B2 AU 2019328556 B2 AU2019328556 B2 AU 2019328556B2 AU 2019328556 A AU2019328556 A AU 2019328556A AU 2019328556 A AU2019328556 A AU 2019328556A AU 2019328556 B2 AU2019328556 B2 AU 2019328556B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
formula
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019328556A
Other languages
English (en)
Other versions
AU2019328556A1 (en
Inventor
Luke W. Ashcraft
Chihyuan Chuang
Kevin Lau
Bradley P. Morgan
Mark VANDERWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2019328556A1 publication Critical patent/AU2019328556A1/en
Application granted granted Critical
Publication of AU2019328556B2 publication Critical patent/AU2019328556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2019328556A 2018-08-31 2019-08-30 Cardiac sarcomere inhibitors Active AU2019328556B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726162P 2018-08-31 2018-08-31
US62/726,162 2018-08-31
PCT/US2019/049118 WO2020047447A1 (en) 2018-08-31 2019-08-30 Cardiac sarcomere inhibitors

Publications (2)

Publication Number Publication Date
AU2019328556A1 AU2019328556A1 (en) 2021-03-11
AU2019328556B2 true AU2019328556B2 (en) 2025-09-04

Family

ID=67953902

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019328556A Active AU2019328556B2 (en) 2018-08-31 2019-08-30 Cardiac sarcomere inhibitors

Country Status (22)

Country Link
US (4) US11414424B2 (https=)
EP (1) EP3843842A1 (https=)
JP (2) JP7447089B2 (https=)
KR (1) KR20210068422A (https=)
CN (2) CN118955409A (https=)
AR (1) AR116283A1 (https=)
AU (1) AU2019328556B2 (https=)
BR (1) BR112021003496A2 (https=)
CA (1) CA3110237A1 (https=)
CL (1) CL2021000481A1 (https=)
CO (1) CO2021003115A2 (https=)
EA (1) EA202190657A1 (https=)
EC (1) ECSP21016009A (https=)
IL (2) IL315709A (https=)
MA (1) MA53491A (https=)
MX (1) MX2021002199A (https=)
NZ (1) NZ773016A (https=)
PH (1) PH12021550400A1 (https=)
SG (1) SG11202101769YA (https=)
TW (1) TWI848972B (https=)
UY (1) UY38358A (https=)
WO (1) WO2020047447A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
US12516016B2 (en) * 2020-03-11 2026-01-06 Sheldon Cao GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
JP7700218B2 (ja) * 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
WO2022105852A1 (zh) * 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
EP4514355A1 (en) 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors
RS67793B1 (sr) 2022-09-02 2026-03-31 Cytokinetics Inc Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
KR100595926B1 (ko) 1998-01-26 2006-07-05 웨인 웨스터만 수동 입력 통합 방법 및 장치
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
ATE552236T1 (de) 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
JP2008521900A (ja) * 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
EP4234017B1 (en) 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
JP2019507110A (ja) 2015-12-17 2019-03-14 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
CN108368098B (zh) 2015-12-18 2022-01-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
RS65302B1 (sr) 2019-07-17 2024-04-30 Cytokinetics Inc Oralne formulacije inhibitora srčanog sarkomera
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
RS67793B1 (sr) 2022-09-02 2026-03-31 Cytokinetics Inc Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
AR116283A1 (es) 2021-04-21
US20230090256A1 (en) 2023-03-23
MX2021002199A (es) 2021-08-16
TWI848972B (zh) 2024-07-21
IL281075A (en) 2021-04-29
CO2021003115A2 (es) 2021-06-10
EA202190657A1 (ru) 2021-07-22
CL2021000481A1 (es) 2021-07-23
US20200109148A1 (en) 2020-04-09
US12275741B2 (en) 2025-04-15
MA53491A (fr) 2021-09-15
IL315709A (en) 2024-11-01
KR20210068422A (ko) 2021-06-09
UY38358A (es) 2020-03-31
US20250276976A1 (en) 2025-09-04
JP2021535164A (ja) 2021-12-16
IL281075B1 (en) 2024-10-01
CA3110237A1 (en) 2020-03-05
JP7447089B2 (ja) 2024-03-11
PH12021550400A1 (en) 2021-12-06
JP7825650B2 (ja) 2026-03-06
CN118955409A (zh) 2024-11-15
US11414424B2 (en) 2022-08-16
AU2019328556A1 (en) 2021-03-11
IL281075B2 (en) 2025-02-01
CN112867539A (zh) 2021-05-28
NZ773016A (en) 2026-03-27
CN112867539B (zh) 2024-08-06
US20240368172A1 (en) 2024-11-07
ECSP21016009A (es) 2021-05-31
US11952381B2 (en) 2024-04-09
TW202023648A (zh) 2020-07-01
EP3843842A1 (en) 2021-07-07
JP2024054409A (ja) 2024-04-16
SG11202101769YA (en) 2021-03-30
WO2020047447A1 (en) 2020-03-05
BR112021003496A2 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
AU2019328556B2 (en) Cardiac sarcomere inhibitors
EP3814343B1 (en) Cardiac sarcomere inhibitors
JP7476216B2 (ja) ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
KR20210013145A (ko) 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법
JP6893516B2 (ja) ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
WO2012101487A1 (en) Di/tri-aza-spiro-c9-c11alkanes
WO2024026484A2 (en) Cdk2 inhibitors and methods of using the same
US20120101110A1 (en) Diaza-spiro[5.5]undecanes
EA045362B1 (ru) Ингибиторы саркомера сердца
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
HK40054614A (en) Cardiac sarcomere inhibitors
HK40054614B (zh) 心脏肌小节抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)